Apollomics (APLM) News Today → America’s worst nightmare? (From Porter & Company) (Ad) Free APLM Stock Alerts $0.34 -0.03 (-8.04%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 10 at 3:30 AM | americanbankingnews.comHC Wainwright Lowers Apollomics (NASDAQ:APLM) Price Target to $2.00May 8, 2024 | markets.businessinsider.comMaintaining Buy Rating on Apollomics Amid Clinical Setbacks and Pipeline PotentialMay 8, 2024 | finance.yahoo.comApollomics Announces Private Placement Financing and Addition to Board of DirectorsApril 25, 2024 | globenewswire.comApollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion GeneApril 17, 2024 | msn.comApollomics (APLM) Price Target Decreased by 58.93% to 5.87April 16, 2024 | finance.yahoo.comApollomics, Inc. (APLM) Interactive Stock Chart - Yahoo FinanceApril 10, 2024 | marketbeat.comApollomics, Inc. (NASDAQ:APLM) Sees Large Increase in Short InterestApollomics, Inc. (NASDAQ:APLM - Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 155,100 shares, a growth of 238.6% from the March 15th total of 45,800 shares. Based on an average daily trading volume, of 216,000 shares, the short-interest ratio is presently 0.7 days. Currently, 0.2% of the shares of the company are sold short.April 10, 2024 | globenewswire.comApollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingApril 3, 2024 | marketbeat.comQ1 2024 EPS Estimates for Apollomics, Inc. Decreased by Analyst (NASDAQ:APLM)Apollomics, Inc. (NASDAQ:APLM - Free Report) - Equities researchers at HC Wainwright decreased their Q1 2024 earnings per share (EPS) estimates for Apollomics in a report released on Monday, April 1st. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.17) per share forApril 2, 2024 | finance.yahoo.comApollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingApril 1, 2024 | marketbeat.comHC Wainwright Trims Apollomics (NASDAQ:APLM) Target Price to $5.00HC Wainwright reduced their price objective on shares of Apollomics from $17.00 to $5.00 and set a "buy" rating for the company in a research report on Monday.March 28, 2024 | msn.comApollomics GAAP EPS of -$2.32March 28, 2024 | globenewswire.comApollomics Highlights Clinical Progress and Reports Full Year 2023 Financial ResultsMarch 27, 2024 | marketbeat.comApollomics (APLM) Set to Announce Quarterly Earnings on ThursdayApollomics (NASDAQ:APLM) will be releasing earnings before the market opens on Thursday, March 28, Zacks reports.March 4, 2024 | finance.yahoo.comApollomics Names Matthew Plunkett as Chief Financial OfficerMarch 4, 2024 | globenewswire.comApollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial OfficerFebruary 22, 2024 | benzinga.comApollomics Stock (NASDAQ:APLM), Short Interest ReportFebruary 12, 2024 | marketbeat.comShort Interest in Apollomics, Inc. (NASDAQ:APLM) Decreases By 54.5%Apollomics, Inc. (NASDAQ:APLM - Get Free Report) was the recipient of a large drop in short interest during the month of January. As of January 31st, there was short interest totalling 63,900 shares, a drop of 54.5% from the January 15th total of 140,500 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average trading volume of 1,980,000 shares, the days-to-cover ratio is presently 0.0 days.February 3, 2024 | marketbeat.comApollomics (NASDAQ:APLM) Stock Price Down 1.2%Apollomics (NASDAQ:APLM) Shares Down 1.2%January 20, 2024 | finanznachrichten.deApollomics Inc.: Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyJanuary 19, 2024 | finance.yahoo.comApollomics Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyJanuary 17, 2024 | stockhouse.comApollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology ConferenceJanuary 3, 2024 | finance.yahoo.comApollomics Completes Patient Enrollment for Phase 3 Trial of Leukemia TreatmentDecember 17, 2023 | morningstar.comApollomics Inc Ordinary Shares - Class A APLMDecember 12, 2023 | morningstar.comApollomics Inc Ordinary Shares - Class ADecember 7, 2023 | finance.yahoo.comApollomics Presents Data from Phase 2 Clinical Trials of Lung Cancer MedicationDecember 4, 2023 | finance.yahoo.comApollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping MutationNovember 28, 2023 | ca.finance.yahoo.comApollomics, Inc. (APLM)November 28, 2023 | finance.yahoo.comApollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)November 16, 2023 | marketwatch.comApollomics Shares More Than Double on Partner's Approval for Commercialization of VebreltinibNovember 16, 2023 | msn.comWhy Is Cancer Firm Apollomics Stock Trading Higher Today?November 16, 2023 | finance.yahoo.comApollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung CancerOctober 31, 2023 | finance.yahoo.comApollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET DysregulationOctober 27, 2023 | msn.comApollomics stock soars 76% following positive report for brain cancer therapyOctober 27, 2023 | benzinga.comWhat's Going On With Apollomics Inc Stock?October 27, 2023 | marketbeat.comTrading was temporarily halted for "APLM" at 09:10 AM with a stated reason of "LULD pause."October 27, 2023 | investorplace.comWhy Is Apollomics (APLM) Stock Up 113% Today?October 26, 2023 | finance.yahoo.comApollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET FusionOctober 24, 2023 | markets.businessinsider.comAnalysts Offer Insights on Financial Companies: W. R. Berkley Corporation (WRB), Apollomics (APLM) and Northwest Bancshares (NWBI)October 24, 2023 | finance.yahoo.comApollomics Treating MET-Altered Cancers: KUNPENG Trial ResultsOctober 23, 2023 | msn.comApollomics stock rallies 35% pre-market on encouraging lung cancer studyOctober 23, 2023 | finance.yahoo.comApollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%October 16, 2023 | finance.yahoo.comApollomics Announces Presentations of Vebreltinib Data at ESMO 2023October 3, 2023 | markets.businessinsider.comBuy Rating on Apollomics Based on Promising Future Prospects and High Potential of Vebreltinib in Cancer TreatmentSeptember 28, 2023 | tmcnet.comApollomics Reports First Half 2023 Financial Results and Provides Corporate UpdateSeptember 15, 2023 | marketbeat.comApollomics, Inc. (NASDAQ:APLM) Sees Large Growth in Short InterestApollomics, Inc. (NASDAQ:APLM - Get Free Report) saw a significant increase in short interest in August. As of August 31st, there was short interest totalling 4,100 shares, an increase of 57.7% from the August 15th total of 2,600 shares. Based on an average daily trading volume, of 21,300 shares, the short-interest ratio is presently 0.2 days. Currently, 0.1% of the company's stock are short sold.July 30, 2023 | finance.yahoo.comAPLM - Apollomics, Inc.July 20, 2023 | finance.yahoo.comRetail investors account for 44% of Apollomics, Inc.'s (NASDAQ:APLM) ownership, while private equity firms account for 21%July 8, 2023 | fool.comApollomics (NASDAQ: APLM)June 19, 2023 | finance.yahoo.comQiming Venture Partners Welcomes Apollomics' Successful IPO on Nasdaq Get Apollomics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter. Email Address America’s worst nightmare? (Ad)What This Group Has Planned for the 2024 Election Will Shock You Controversial new exposé reveals what’s really going on in America, what it means for your money, and what you must do to protect your assets before it’s too late. Click here to watch this bombshell exposé now. APLM Media Mentions By Week APLM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APLM News Sentiment▼0.400.58▲Average Medical News Sentiment APLM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APLM Articles This Week▼71▲APLM Articles Average Week Get Apollomics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ProMIS Neurosciences News Today Marker Therapeutics News Today CASI Pharmaceuticals News Today BriaCell Therapeutics News Today JanOne News Today DURECT News Today Fortress Biotech News Today ImmunoPrecise Antibodies News Today Spruce Biosciences News Today Viracta Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APLM) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
